Morgan Stanley’s Akcea Therapeutics Inc AKCA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-195,555
| Closed | -$3.55M | – | 7281 |
|
|
2020
Q3 | $3.55M | Buy |
195,555
+171,094
| +699% | +$2.43M | ﹤0.01% | 3066 |
|
|
2020
Q2 | $335K | Buy |
24,461
+10,718
| +78% | +$165K | ﹤0.01% | 4807 |
|
|
2020
Q1 | $196K | Sell |
13,743
-14,625
| -52% | -$240K | ﹤0.01% | 4873 |
|
|
2019
Q4 | $480K | Sell |
28,368
-213,718
| -88% | -$3.98M | ﹤0.01% | 4943 |
|
|
2019
Q3 | $3.73M | Buy |
242,086
+14,467
| +6% | +$308K | ﹤0.01% | 3196 |
|
|
2019
Q2 | $5.34M | Buy |
227,619
+42,720
| +23% | +$1.06M | ﹤0.01% | 2861 |
|
|
2019
Q1 | $5.24M | Buy |
184,899
+307
| +0.2% | +$8.94K | ﹤0.01% | 2658 |
|
|
2018
Q4 | $5.56M | Buy |
184,592
+22,635
| +14% | +$634K | ﹤0.01% | 2774 |
|
|
2018
Q3 | $5.67M | Buy |
161,957
+34,668
| +27% | +$1.05M | ﹤0.01% | 3044 |
|
|
2018
Q2 | $3.02M | Buy |
127,289
+91,219
| +253% | +$2.18M | ﹤0.01% | 3692 |
|
|
2018
Q1 | $924K | Buy |
36,070
+2,489
| +7% | +$53.6K | ﹤0.01% | 4600 |
|
|
2017
Q4 | $583K | Buy |
33,581
+9,964
| +42% | +$195K | ﹤0.01% | 4885 |
|
|
2017
Q3 | $653K | Buy |
+23,617
| New | +$437K | ﹤0.01% | 4710 |
|
Morgan Stanley's AKCA Position: Q4 2020 in Review
Morgan Stanley sold out of Akcea Therapeutics Inc (AKCA) in Q4 2020, closing a stake of 195,555 shares — an estimated $3.55M sold.
Morgan Stanley first reported a position in AKCA in Q3 2017 and held it in 13 quarters. The position peaked at $5.67M in Q3 2018. 0 funds tracked by Wall St. Rank hold AKCA as of Q4 2020.
- Morgan Stanley reported no remaining Akcea Therapeutics Inc position as of Q4 2020 after selling out during the quarter.
- Morgan Stanley sold 195,555 Akcea Therapeutics Inc shares in Q4 2020, an estimated $3.55M.
- Morgan Stanley first reported a position in Akcea Therapeutics Inc in Q3 2017 and held it in 13 quarters.
- Morgan Stanley's Akcea Therapeutics Inc position peaked at $5.67M in Q3 2018.
- 0 funds tracked by Wall St. Rank held Akcea Therapeutics Inc as of Q4 2020.
Based on Morgan Stanley's 13F filing for Q4 2020, filed 16 Feb 2021.